Icure Pharmaceutical Incorporation
Icure Pharmaceutical Incorporation, a biopharmaceutical company, researches, develops, and sells pharmaceutical and cosmetic products in South Korea. The company offers functional, nature-derived, derma, and customized cosmetics products. It also offers eye gel, hydro nude gel, lip gel mask, and functional patch products; and sheet, mud, foil, and melting masks. In addition, the company provides … Read more
Market Cap & Net Worth: Icure Pharmaceutical Incorporation (175250)
Icure Pharmaceutical Incorporation (KQ:175250) has a market capitalization of $55.38 Million (₩81.09 Billion) as of March 19, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #21540 globally and #1030 in its home market, demonstrating a 20.22% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Icure Pharmaceutical Incorporation's stock price ₩2170.00 by its total outstanding shares 37369700 (37.37 Million).
Icure Pharmaceutical Incorporation Market Cap History: 2018 to 2025
Icure Pharmaceutical Incorporation's market capitalization history from 2018 to 2025. Data shows change from $251.79 Million to $55.38 Million (-25.91% CAGR).
Index Memberships
Icure Pharmaceutical Incorporation is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$167.85 Billion | 0.03% | #474 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$167.85 Billion | 0.03% | #474 of 1384 |
Weight: Icure Pharmaceutical Incorporation's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Icure Pharmaceutical Incorporation Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Icure Pharmaceutical Incorporation's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Icure Pharmaceutical Incorporation's market cap is 0.00 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.04x
Icure Pharmaceutical Incorporation's market cap is 0.04 times its annual earnings
10.35x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $251.79 Million | $33.32 Billion | -$7.89 Billion | 0.01x | N/A |
| 2019 | $275.41 Million | $60.92 Billion | -$8.75 Billion | 0.00x | N/A |
| 2020 | $479.96 Million | $90.14 Billion | -$12.61 Billion | 0.01x | N/A |
| 2021 | $332.77 Million | $64.28 Billion | -$38.17 Billion | 0.01x | N/A |
| 2022 | $65.21 Million | $59.37 Billion | -$41.77 Billion | 0.00x | N/A |
| 2023 | $53.34 Million | $56.81 Billion | -$31.42 Billion | 0.00x | N/A |
| 2024 | $46.32 Million | $69.21 Billion | $1.05 Billion | 0.00x | 0.04x |
Competitor Companies of 175250 by Market Capitalization
Companies near Icure Pharmaceutical Incorporation in the global market cap rankings as of March 19, 2026.
Key companies related to Icure Pharmaceutical Incorporation by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Icure Pharmaceutical Incorporation Historical Marketcap From 2018 to 2025
Between 2018 and today, Icure Pharmaceutical Incorporation's market cap moved from $251.79 Million to $ 55.38 Million, with a yearly change of -25.91%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | ₩55.38 Million | +19.56% |
| 2024 | ₩46.32 Million | -13.16% |
| 2023 | ₩53.34 Million | -18.20% |
| 2022 | ₩65.21 Million | -80.40% |
| 2021 | ₩332.77 Million | -30.67% |
| 2020 | ₩479.96 Million | +74.27% |
| 2019 | ₩275.41 Million | +9.38% |
| 2018 | ₩251.79 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Icure Pharmaceutical Incorporation was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $55.38 Million USD |
| MoneyControl | $55.38 Million USD |
| MarketWatch | $55.38 Million USD |
| marketcap.company | $55.38 Million USD |
| Reuters | $55.38 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.